Skip to main content
My Experience
Login Required
Program
Full Program
Browse By Date
Thursday, April 20, 2023
Friday, April 21, 2023
Saturday, April 22, 2023
Browse By Title
Browse By Presenter
CME Program
Networking Opportunities
Industry Session
Abstracts and ePosters
Browse by Track
Browse by Poster Title
Browse by Poster Number
Browse by Poster Presenter
Exhibitors
Browse by Company
Sponsors
Browse by Company
Industry Sessions
Attendees
Coming Soon!
CME and Evaluation Information
Coming Soon!
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Toggle navigation
Login
Search
Home
My Experience
Login Required
Program
Full Program
Browse By Date
Thursday, April 20, 2023
Friday, April 21, 2023
Saturday, April 22, 2023
Browse By Title
Browse By Presenter
CME Program
Networking Opportunities
Industry Session
Abstracts and ePosters
Browse by Track
Browse by Poster Title
Browse by Poster Number
Browse by Poster Presenter
Exhibitors
Browse by Company
Sponsors
Browse by Company
Industry Sessions
Attendees
Coming Soon!
CME and Evaluation Information
Coming Soon!
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Tweets by 2023 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
3 results found
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
G
Giles, Rachel
International Kidney Cancer Coalition
6
:
2022 Global Patient Survey: Reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas
Rachel Giles
Favorite
Gruenwald, Viktor
Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
12
:
T-Rex Study: Real-world evidence and patient-reported outcomes of mRCC patients treated first-line with tivozanib
Viktor Gruenwald
Favorite
32
:
Clinical benefit of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after checkpoint inhibitor (CPI) therapy: interim results from the Phase 2 CaboPoint trial
Viktor Gruenwald
Favorite
Back to Top
